Home Clinical trials For professionals Ovary DS3939-077

DS3939-077

Phase 1/2, Open-Label, Multicenter, First-In-Human Study of DS-3939a in Subjects with Advanced Solid Tumors

On hold
Grade
High grade, Low grade, Other / unknown
Prior lines
1, 2, 3, 4, >4
Histology
Serous, Endometrioid Mucinous Clear-cell Other (bv. mixed/rare)
Platin
Platinum resistant
Secondary platinum refractory
Primary platinum refractory
Phase
I
IMP
DS3939a
principal investigator
Prof. Dr. Els Van Nieuwenhuysen

Treatment

The treatment option in this study is DS3939a. We are curently including in Part I.
 

Treatment duration

The treatment can continue until disease progression, unacceptable toxicity or withdrawal of consent.

Eligibility

Main inclusion criteria:

  • Has a histologically or cytologically documented locally advanced, metastatic, or unresectable solid malignant tumors
  • Measurable disease, per RECIST v1.1

Main exclusion criteria:

  • Has had prior treatment targeting mucin 1 (MUC1) or TA-MUC1
  • Has a history of noninfectious interstitial lung disease (ILD)/pneumonitis (including suspected one), has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening

Disclaimer: Criteria might change during the course of the study due to amendments. Inclusion in the trial remains the responsibility of the principal investigator of the trial and will depend on patient eligibility and slot availability.

Contact

In case you feel your patient might be eligible for this trial or in case you want to have more information about this trial, please feel free to contact us via: lgog@uzleuven.be

More information on this trial (NCT05875168)